Literature DB >> 20175198

Loss of expression of ZAC/PLAGL1 in diffuse large B-cell lymphoma is independent of promoter hypermethylation.

Elizabeth M A Valleley1, Sarah F Cordery, Ian M Carr, Kenneth A MacLennan, David T Bonthron.   

Abstract

ZAC/PLAGL1 is a ubiquitously expressed, imprinted tumor suppressor gene located on 6q24, a chromosomal region that is frequently deleted in diffuse large B-cell lymphoma (DLBCL). Like p53, ZAC regulates cell cycle arrest and apoptosis concomitantly, and loss of expression is implicated in tumorigenesis in a variety of different cancers. In most tissues, ZAC transcription is monoallelic and driven by the paternal allele of promoter P1, which lies within a differentially methylated CpG island (DMR). In human blood cells, ZAC transcription is driven by promoter P2, which lies within an unmethylated CpG island and produces biallelic transcripts. Previous reports of epigenetic changes of ZAC in tumors have focused on P1, showing frequent loss of expression caused by paternal allele hypermethylation or loss of heterozygosity (LOH). As ZAC expression in normal B lymphocytes is derived from P2, in DLBCL we analyzed both promoters for gene expression, LOH and abnormal methylation. Loss of P2 transcription was observed in 8 of 11 lymphomas (73%), even though the P2 CpG island remained unmethylated. Three lymphomas showed evidence of LOH (23%), and abnormal methylation of the P1 DMR was observed in an additional four (31%), despite minimal P1 activity in normal B lymphocytes. These data indicate that downregulation of ZAC occurs in DLBCL, as in other cancers. However, unlike P1, transcriptional repression of P2 is not caused by hypermethylation of its associated CpG island in tumors. The mechanistic relationship between altered ZAC expression and epigenetic changes at its promoters thus appears more complex than previously supposed. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20175198     DOI: 10.1002/gcc.20758

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

Review 1.  PLAGL1: an important player in diverse pathological processes.

Authors:  Ana F Vega-Benedetti; Cinthia Saucedo; Patrizia Zavattari; Roberta Vanni; José L Zugaza; Luis Antonio Parada
Journal:  J Appl Genet       Date:  2016-06-16       Impact factor: 3.240

2.  Correlation between gastric carcinoma and ZAC gene-associated microsatellite instability and loss of heterozygosity.

Authors:  Xiao-Yan Zhu; Ji-Yao Yang; Ying He; Guo-Hong Liu; Yun Sun; Yi Ding
Journal:  Oncol Lett       Date:  2017-06-15       Impact factor: 2.967

3.  NDRG1-PLAG1 and TRPS1-PLAG1 Fusion Genes in Chondroid Syringoma.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Kristin Andersen; Marius Lund-Iversen; Ingvild Lobmaier; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2020 May-Jun       Impact factor: 4.069

4.  A tissue-specific promoter derived from a SINE retrotransposon drives biallelic expression of PLAGL1 in human lymphocytes.

Authors:  Claire E L Smith; Alexia Alexandraki; Sarah F Cordery; Rekha Parmar; David T Bonthron; Elizabeth M A Valleley
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

Review 5.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

6.  The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cells.

Authors:  S F Landrette; D Madera; F He; L H Castilla
Journal:  Leukemia       Date:  2011-01-25       Impact factor: 11.528

7.  Prognostic value of PLAGL1-specific CpG site methylation in soft-tissue sarcomas.

Authors:  Anne-Lise Peille; Veronique Brouste; Audrey Kauffmann; Pauline Lagarde; Valerie Le Morvan; Jean-Michel Coindre; Frederic Chibon; Laurence Bresson-Bepoldin
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.